Cancer Diagnostics Market by Product (Consumables (Anitibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals)- Global Forecasts to 2026
The global cancer diagnostics market size is projected to reach USD 26.6 billion by 2026 from USD 17.2 billion in 2021, at a CAGR of 11.5% from 2021 to 2026. Growth in this market is driven by the rising prevalence of cancer, and growing initiatives undertaken by government bodies to create awareness about cancer, the increasing number of private diagnostic centers.
“Consumables segment to witness the highest growth during the forecast period.”
Based on the product, the cancer diagnostics market is segmented into consumables and instruments. The consumables segment is projected to grow at the highest CAGR during the forecast period. high prevalence of cancer, number of reagent rental agreements, and the growing application of innovative technologies and methodologies are the major factor supporting the growth of this segment.
“Breast cancer segment to register the highest growth in the cancer diagnostics market during the forecast period.”
Based on the application, the cancer diagnostics market is segmented into breast cancer, lung cancer, colorectal cancer, melanoma, and other cancer. The breast cancer segment is projected to witness the highest growth in the cancer diagnostics market during the forecast period. The increasing incidence of cancer and technological advancement are the major factors supporting the growth of this segment.
“Asia Pacific is estimated to register the highest CAGR during the forecast period.”
In this report, the cancer diagnostics market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by The increasing incidence of cancer, increasing number of patients visiting hospitals, and growing awareness regarding early diagnosis.
Breakdown of supply-side primary interviews, by company type, designation, and region:
This report studies the cancer diagnostics market based on product, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total cancer diagnostics market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
“Consumables segment to witness the highest growth during the forecast period.”
Based on the product, the cancer diagnostics market is segmented into consumables and instruments. The consumables segment is projected to grow at the highest CAGR during the forecast period. high prevalence of cancer, number of reagent rental agreements, and the growing application of innovative technologies and methodologies are the major factor supporting the growth of this segment.
“Breast cancer segment to register the highest growth in the cancer diagnostics market during the forecast period.”
Based on the application, the cancer diagnostics market is segmented into breast cancer, lung cancer, colorectal cancer, melanoma, and other cancer. The breast cancer segment is projected to witness the highest growth in the cancer diagnostics market during the forecast period. The increasing incidence of cancer and technological advancement are the major factors supporting the growth of this segment.
“Asia Pacific is estimated to register the highest CAGR during the forecast period.”
In this report, the cancer diagnostics market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by The increasing incidence of cancer, increasing number of patients visiting hospitals, and growing awareness regarding early diagnosis.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)
- By Designation: C-level (30%), Director-level (34%), and Others (36%)
- By Region: North America (40%), Europe (28%), AsiaPacific (20%), and Rest of the World(12%)
- GE Healthcare (US)
- Abbott Laboratories (US)
- Hologic Inc. (US)
- Agilent Technologies Inc.(US)
- Roche Diagnostics (Switzerland)
- FUJIFILM Corporation (Japan)
- Danaher Corporation (US)
- DiaSorin S.P.A. (Italy)
- Myriad Genetics Inc. (US)
- Siemens Healthineers AG (Germany)
- BD (US)
- bioM?rieux SA (France)
- Bio-Rad Laboratories (US)
- Cancer Diagnostics Inc. (US)
- Vela Diagnostics (Singapore)
- Roche Diagnostics (Switzerland)
- AMOY Diagnostics CO. LTD. (China)
- Quidel Corporation (US)
- Bio SB (US)
- Biocartis NV (Belgium)
- Exact Science (US)
This report studies the cancer diagnostics market based on product, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total cancer diagnostics market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on cancer diagnostics products offered by the top 23 players in the cancer diagnostics market. The report analyzes the cancer diagnostics market by product, technology, application, end user, and region.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.
- Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the cancer diagnostics market
- Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the cancer diagnostics market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 6 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 COVID-19 HEALTH ASSESSMENT
2.7 COVID-19 ECONOMIC ASSESSMENT
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
3 EXECUTIVE SUMMARY
FIGURE 10 CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021 VS. 2026 (USD BILLION)
FIGURE 11 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD BILLION)
FIGURE 12 CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION)
FIGURE 13 CANCER DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
FIGURE 14 CANCER DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD BILLION)
4 PREMIUM INSIGHTS
4.1 CANCER DIAGNOSTICS MARKET OVERVIEW
FIGURE 15 INCREASING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
DURING THE FORECAST PERIOD
4.2 CANCER DIAGNOSTICS MARKET, BY PRODUCT
FIGURE 16 INSTRUMENTS SEGMENT ACCOUNTED FOR THE LARGEST
MARKET SHARE IN 2020
4.3 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY, 2020
FIGURE 17 US DOMINATED THE NORTH AMERICAN CANCER DIAGNOSTICS
MARKET IN 2020
4.4 GEOGRAPHICAL SNAPSHOT OF THE CANCER DIAGNOSTICS MARKET
FIGURE 18 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 CANCER DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of cancer
TABLE 1 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS.
2030 VS. 2040 (MILLION)
TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
5.2.1.2 Growth in the number of private diagnostic centers
5.2.1.3 Availability of reimbursement
5.2.2 RESTRAINTS
5.2.2.1 High capital investments and low cost-benefit ratio for biomarkers
5.2.2.2 High cost of diagnostic imaging systems
5.2.2.3 Product recalls and failure
5.2.3 OPPORTUNITIES
5.2.3.1 Growing focus on personalized medicine
FIGURE 20 RISING NUMBER OF PERSONALIZED MEDICINES, 2008–2020
5.2.3.2 Companion diagnostics
5.2.3.3 Recommendations for cancer screening
5.2.3.4 Emerging countries
5.2.4 CHALLENGES
5.2.4.1 Increasing adoption of refurbished diagnostic imaging systems
5.2.4.2 Lack of skilled professionals
TABLE 3 NUMBER OF PATHOLOGISTS PER 10,000 POPULATION, BY COUNTRY, 2018
5.2.4.3 Inadequate infrastructure and low awareness in middle- and
low-income countries
5.2.5 TRENDS
5.2.5.1 Rental agreements
5.3 COVID-19 IMPACT ANALYSIS
5.4 VALUE CHAIN ANALYSIS
FIGURE 21 MAJOR VALUE IS ADDED DURING THE MANUFACTURING &
ASSEMBLY PHASES
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 22 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.6 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT FROM NEW ENTRANTS
5.6.2 INTENSITY OF COMPETITIVE RIVALRY
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 BARGAINING POWER OF SUPPLIERS
5.6.5 THREAT FROM SUBSTITUTES
5.7 TECHNOLOGY ANALYSIS
5.8 REGULATORY LANDSCAPE
FIGURE 23 510(K) APPROVAL PROCESS
5.9 PATENT ANALYSIS
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR MAMMOGRAPHY SYSTEMS
TABLE 4 IMPORT DATA FOR MAMMOGRAPHY SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
TABLE 5 EXPORT DATA FOR MAMMOGRAPHY SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
5.10.2 TRADE ANALYSIS FOR MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS
TABLE 6 IMPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
TABLE 7 EXPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
5.11 PRICING ANALYSIS
TABLE 8 PRICES OF CANCER DIAGNOSTIC PRODUCTS
5.12 ECOSYSTEM ANALYSIS: CANCER DIAGNOSTICS MARKET
5.12.1 ROLE IN ECOSYSTEM
5.13 YCC SHIFT
6 CANCER DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 9 CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 CONSUMABLES
TABLE 10 CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 11 CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2019–2026 (USD MILLION)
6.2.1 ANTIBODIES
6.2.1.1 Antibodies accounted for the largest share of the cancer diagnostic consumables market in 2020
TABLE 12 CANCER DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
6.2.2 KITS & REAGENTS
6.2.2.1 Use of kits is increasing among end users owing to their ease of use
TABLE 13 CANCER DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2019–2026 (USD MILLION)
6.2.3 PROBES
6.2.3.1 Abbott and Agilent Technologies are some of the leading players operating in this market segment
TABLE 14 CANCER DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2019–2026 (USD MILLION)
6.2.4 OTHER CONSUMABLES
TABLE 15 CANCER DIAGNOSTICS MARKET FOR OTHER CONSUMABLES, BY REGION, 2019–2026 (USD MILLION)
6.3 INSTRUMENTS
TABLE 16 CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 17 CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.1 PATHOLOGY-BASED INSTRUMENTS
TABLE 18 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 19 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.1 Slide staining systems
6.3.1.1.1 Slide staining systems accounted for the largest share of the pathology-based instruments market
TABLE 20 CANCER DIAGNOSTICS MARKET FOR SLIDE STAINING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.2 Tissue processing systems
6.3.1.2.1 Tissue processing systems are used for the automatic processing of tissue samples
TABLE 21 CANCER DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.3 Cell processors
6.3.1.3.1 Cell processors are used to remove unwanted matter from cytology samples
TABLE 22 CANCER DIAGNOSTICS MARKET FOR CELL PROCESSORS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.4 PCR instruments
6.3.1.4.1 Cost-effectiveness of PCR is driving the growth of this market segment
TABLE 23 CANCER DIAGNOSTICS MARKET FOR PCR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.5 NGS instruments
6.3.1.5.1 NGS is an emerging technology for cancer diagnostics
TABLE 24 CANCER DIAGNOSTICS MARKET FOR NGS INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.6 Microarrays
6.3.1.6.1 DNA microarrays are useful for the determination of primary sites in metastatic carcinomas
TABLE 25 CANCER DIAGNOSTICS MARKET FOR MICROARRAYS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.7 Other pathology-based instruments
TABLE 26 CANCER DIAGNOSTICS MARKET FOR OTHER PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.2 IMAGING INSTRUMENTS
TABLE 27 CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 28 CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.2.1 CT systems
6.3.2.1.1 Technological advancements in CT to drive the growth of this market segment
TABLE 29 CANCER DIAGNOSTICS MARKET FOR CT SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.2.2 Ultrasound systems
6.3.2.2.1 Increasing incidence of cancer to drive the growth of this market segment
TABLE 30 CANCER DIAGNOSTICS MARKET FOR ULTRASOUND SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.2.3 MRI systems
6.3.2.3.1 Use of MRI in cancer diagnostics has increased
over the years
TABLE 31 CANCER DIAGNOSTICS MARKET FOR MRI SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.2.4 Mammography systems
6.3.2.4.1 Increasing incidence of breast cancer to drive the growth of this market segment
TABLE 32 CANCER DIAGNOSTICS MARKET FOR MAMMOGRAPHY SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.2.5 Nuclear imaging systems
6.3.2.5.1 Technological advancements in nuclear imaging systems to drive the growth of this market segment
TABLE 33 CANCER DIAGNOSTICS MARKET FOR NUCLEAR IMAGING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.3 BIOPSY INSTRUMENTS
6.3.3.1 Increasing prevalence of cancer to drive the growth of this
market segment
TABLE 34 CANCER DIAGNOSTICS MARKET FOR BIOPSY INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
7 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 35 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
7.2 IVD TESTING
TABLE 36 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 37 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY REGION, 2019–2026 (USD MILLION)
7.2.1 POLYMERASE CHAIN REACTION
7.2.1.1 Physicians prefer PCR-based diagnostic tests as they provide simple representations of genomic data
TABLE 38 CANCER DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2019–2026 (USD MILLION)
7.2.2 IN SITU HYBRIDIZATION
7.2.2.1 ISH is used for the identification of specific mRNA species within sample cells
TABLE 39 CANCER DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2019–2026 (USD MILLION)
7.2.3 IMMUNOHISTOCHEMISTRY
7.2.3.1 Increasing use of IHC tests for cancer diagnostics to boost
the market growth
TABLE 40 CANCER DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2019–2020 (USD MILLION)
7.2.4 NEXT-GENERATION SEQUENCING
7.2.4.1 NGS dominated the IVD testing market in 2020
TABLE 41 CANCER DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
7.2.5 IMMUNOASSAY
7.2.5.1 Immunoassay segment accounted for the second-largest share of the cancer diagnostics market for IVD testing
TABLE 42 CANCER DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY REGION, 2019–2026 (USD MILLION)
7.2.6 MICROARRAY
7.2.6.1 Cost-effectiveness of the microarray technology to
support market growth
TABLE 43 CANCER DIAGNOSTICS MARKET FOR MICROARRAY, BY REGION, 2019–2026 (USD MILLION)
7.2.7 FLOW CYTOMETRY
7.2.7.1 Flow cytometry tools help to detect the number of chromosomes to determine the malignancy of a tumor
TABLE 44 CANCER DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY REGION, 2019–2026 (USD MILLION)
7.2.8 OTHER IVD TECHNOLOGIES
TABLE 45 CANCER DIAGNOSTICS MARKET FOR OTHER IVD TECHNOLOGIES, BY REGION, 2019–2026 (USD MILLION)
7.3 IMAGING TECHNOLOGIES
TABLE 46 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 47 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2019–2026 (USD MILLION)
7.3.1 MAGNETIC RESONANCE IMAGING
7.3.1.1 Technological advancements to boost the growth of the MRI market
TABLE 48 CANCER DIAGNOSTICS MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2019–2026 (USD MILLION)
7.3.2 COMPUTED TOMOGRAPHY
7.3.2.1 CT is a widely used technique in cancer diagnostics
TABLE 49 CANCER DIAGNOSTICS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2019–2026 (USD MILLION)
7.3.3 NUCLEAR IMAGING
7.3.3.1 PET is a widely used nuclear imaging technique in cancer diagnostics
TABLE 50 CANCER DIAGNOSTICS MARKET FOR NUCLEAR IMAGING, BY REGION, 2019–2026 (USD MILLION)
7.3.4 MAMMOGRAPHY
7.3.4.1 Increasing government initiatives for breast cancer screening to drive the growth of this market segment
TABLE 51 CANCER DIAGNOSTICS MARKET FOR MAMMOGRAPHY, BY REGION, 2019–2026 (USD MILLION)
7.3.5 ULTRASOUND
7.3.5.1 Adoption of POC ultrasound for diagnostic purposes to support market growth
TABLE 52 CANCER DIAGNOSTICS MARKET FOR ULTRASOUND, BY REGION, 2019–2026 (USD MILLION)
7.4 BIOPSIES
TABLE 53 CANCER DIAGNOSTICS MARKET FOR BIOPSIES, BY REGION, 2019–2026 (USD MILLION)
8 CANCER DIAGNOSTICS MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 54 CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
8.2 BREAST CANCER
8.2.1 BREAST CANCER SEGMENT TO ACCOUNT FOR THE LARGEST SHARE DURING THE FORECAST PERIOD
TABLE 55 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 56 CANCER DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
8.3 LUNG CANCER
8.3.1 LUNG CANCER SEGMENT ACCOUNTED FOR THE SECOND-
LARGEST SHARE IN 2020
TABLE 57 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 58 CANCER DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
8.4 COLORECTAL CANCER
8.4.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO
DRIVE MARKET GROWTH
TABLE 59 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 60 CANCER DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2026 (USD MILLION)
8.5 MELANOMA
8.5.1 INCREASING INCIDENCE OF MELANOMA TO DRIVE MARKET GROWTH
TABLE 61 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 62 CANCER DIAGNOSTICS MARKET FOR MELANOMA, BY REGION, 2019–2026 (USD MILLION)
8.6 OTHER CANCERS
TABLE 63 CANCER DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
9 CANCER DIAGNOSTICS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 64 CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 HOSPITALS
9.2.1 HOSPITALS ARE THE LARGEST END USERS OF
CANCER DIAGNOSTIC PRODUCTS
TABLE 65 CANCER DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2019–2026 (USD MILLION)
9.3 DIAGNOSTIC LABORATORIES
9.3.1 INCREASING INCIDENCE OF CANCER TO DRIVE THE GROWTH OF
THIS SEGMENT
TABLE 66 CANCER DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
10 CANCER DIAGNOSTICS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 67 CANCER DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 24 NORTH AMERICA: CANCER DIAGNOSTICS MARKET SNAPSHOT
TABLE 68 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 69 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 70 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 71 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 72 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 73 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 74 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 75 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 76 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 77 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 78 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 US is expected to be dominant in the North American market
TABLE 79 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 80 US: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 81 US: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 82 US: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 83 US: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 84 US: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 85 US: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 86 US: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 US: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 US: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 89 US: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 High prevalence of cancer in Canada is expected to
support market growth
TABLE 90 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 91 CANADA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 92 CANADA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 93 CANADA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 94 CANADA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 95 CANADA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 96 CANADA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 97 CANADA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 98 CANADA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 99 CANADA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 100 CANADA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 101 EUROPE: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 102 EUROPE: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 103 EUROPE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 104 EUROPE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 EUROPE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 106 EUROPE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 107 EUROPE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 108 EUROPE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 109 EUROPE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 110 EUROPE: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 111 EUROPE: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth
TABLE 112 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 113 GERMANY: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 114 GERMANY: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 115 GERMANY: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 GERMANY: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 GERMANY: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 118 GERMANY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 119 GERMANY: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 120 GERMANY: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 GERMANY: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 122 GERMANY: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Government initiatives to drive market growth in the UK
TABLE 123 UK: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 124 UK: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 125 UK: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 126 UK: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 127 UK: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 128 UK: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 129 UK: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 130 UK: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 131 UK: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 132 UK: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government funding for cancer diagnosis and prevention to support the market growth
TABLE 133 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 134 FRANCE: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 135 FRANCE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 136 FRANCE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 137 FRANCE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 138 FRANCE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 139 FRANCE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 140 FRANCE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 141 FRANCE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 142 FRANCE: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 143 FRANCE: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 High incidence of cancer to support the market growth in Italy
TABLE 144 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 145 ITALY: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 146 ITALY: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 147 ITALY: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 148 ITALY: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 149 ITALY: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 150 ITALY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 151 ITALY: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 152 ITALY: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 153 ITALY: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 154 ITALY: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 High incidence of chronic diseases to drive the market
growth in Spain
TABLE 155 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 156 SPAIN: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 157 SPAIN: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 158 SPAIN: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 159 SPAIN: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 160 SPAIN: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 161 SPAIN: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 162 SPAIN: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 163 SPAIN: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 164 SPAIN: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 165 SPAIN: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 166 LUNG CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025
TABLE 167 LIVER CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025
TABLE 168 BREAST CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025
TABLE 169 ROE: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 170 ROE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 171 ROE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 172 ROE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 173 ROE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 174 ROE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 175 ROE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 176 ROE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 177 ROE: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 178 ROE: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 25 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET SNAPSHOT
TABLE 179 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 180 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 181 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 182 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 183 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-
BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 184 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 185 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 186 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 187 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 188 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 189 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Increasing healthcare expenditure to drive market growth in China
TABLE 190 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 191 CHINA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 192 CHINA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 193 CHINA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 194 CHINA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 CHINA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 196 CHINA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 197 CHINA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 198 CHINA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 199 CHINA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 200 CHINA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Advanced healthcare infrastructure to support market
growth in Japan
TABLE 201 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 202 JAPAN: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 203 JAPAN: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 204 JAPAN: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 205 JAPAN: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 206 JAPAN: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 207 JAPAN: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 208 JAPAN: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 209 JAPAN: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 210 JAPAN: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 211 JAPAN: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Expanding healthcare sector in the country to drive market growth
TABLE 212 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 213 INDIA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 214 INDIA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 215 INDIA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 216 INDIA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 217 INDIA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 218 INDIA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 219 INDIA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 220 INDIA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 221 INDIA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 222 INDIA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 223 INCIDENCE OF CANCER IN ROAPAC COUNTRIES
TABLE 224 ROAPAC: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 225 ROAPAC: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 226 ROAPAC: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 227 ROAPAC: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 228 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 229 ROAPAC: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 230 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 231 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 232 ROAPAC: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 233 ROAPAC: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 234 ROW: CANCER DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 235 ROW: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 236 ROW: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 237 ROW: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 238 ROW: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 239 ROW: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 240 ROW: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 241 ROW: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 242 ROW: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 243 ROW: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 244 ROW: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5.1 LATIN AMERICA
10.5.1.1 Increasing number of cancer screening programs to
support market growth
TABLE 245 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 246 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 247 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 248 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 249 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 250 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 251 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-
BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 252 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 253 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 254 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 255 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 256 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 257 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5.2 MIDDLE EAST & AFRICA
10.5.2.1 Increasing incidence of cancer in the Middle East & Africa to
drive market growth
TABLE 258 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 259 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 260 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 261 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 262 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 263 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 264 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 265 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 266 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 267 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 268 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
FIGURE 26 KEY DEVELOPMENTS IN THE CANCER DIAGNOSTICS MARKET, JANUARY 2018–APRIL 2021
FIGURE 27 MARKET EVOLUTION MATRIX: JANUARY 2018 TO APRIL 2021
11.2 MARKET SHARE ANALYSIS
TABLE 269 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES:
DEGREE OF COMPETITION
TABLE 270 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS: DEGREE OF COMPETITION
TABLE 271 CANCER DIAGNOSTICS MARKET FOR BIOPSY INSTRUMENTS:
DEGREE OF COMPETITION
11.3 COMPANY EVALUATION MATRIX
11.3.1 STARS
11.3.2 EMERGING LEADERS
11.3.3 PERVASIVE PLAYERS
11.3.4 PARTICIPANTS
FIGURE 28 VENDOR DIVE: CANCER DIAGNOSTICS MARKET
11.4 COMPETITIVE LEADERSHIP MAPPING (SMES/ START-UPS)
11.4.1 PROGRESSIVE COMPANIES
11.4.2 STARTING BLOCKS
11.4.3 RESPONSIVE COMPANIES
11.4.4 DYNAMIC COMPANIES
FIGURE 29 VENDOR DIVE MATRIX FOR SMES & START-UPS:
CANCER DIAGNOSTICS MARKET
11.5 COMPETITIVE SCENARIO
11.5.1 PRODUCT LAUNCHES & APPROVALS
TABLE 272 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2018–APRIL 2021
11.5.2 DEALS
TABLE 273 KEY DEALS, JANUARY 2018–APRIL 2021
11.5.3 OTHER DEVELOPMENTS
TABLE 274 OTHER KEY DEVELOPMENTS, JANUARY 2018–APRIL 2021
11.5.4 COMPANY FOOTPRINT
TABLE 275 COMPANY FOOTPRINT
TABLE 276 COMPANY PRODUCT FOOTPRINT
TABLE 277 COMPANY APPLICATION FOOTPRINT
TABLE 278 COMPANY GEOGRAPHICAL FOOTPRINT
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, and Right to Win)*
12.1.1 GE HEALTHCARE
TABLE 279 GE HEALTHCARE: BUSINESS OVERVIEW
FIGURE 30 GE HEALTHCARE: COMPANY SNAPSHOT (2020)
12.1.2 BECTON, DICKINSON AND COMPANY
TABLE 280 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 31 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
12.1.3 ROCHE DIAGNOSTICS
TABLE 281 F. HOFFMAN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
12.1.4 DANAHER CORPORATION
TABLE 282 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 33 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
12.1.5 THERMO FISHER SCIENTIFIC
TABLE 283 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
12.1.6 ABBOTT LABORATORIES
TABLE 284 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
12.1.7 QIAGEN N.V.
TABLE 285 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 36 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
12.1.8 AGILENT TECHNOLOGIES INC.
TABLE 286 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
FIGURE 37 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2020)
12.1.9 ILLUMINA, INC.
TABLE 287 ILLUMINA INC.: BUSINESS OVERVIEW
FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
12.1.10 SIEMENS HEALTHINEERS AG
TABLE 288 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
12.1.11 DIASORIN S.P.A.
TABLE 289 DIASORIN S.P.A.: BUSINESS OVERVIEW
FIGURE 40 DIASORIN S.P.A.: COMPANY SNAPSHOT (2019)
12.1.12 MYRIAD GENETICS INC.
TABLE 290 MYRIAD GENETICS INC.: BUSINESS OVERVIEW
FIGURE 41 MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2020)
12.1.13 HOLOGIC, INC.
TABLE 291 HOLOGIC, INC.: BUSINESS OVERVIEW
FIGURE 42 HOLOGIC INC.: COMPANY SNAPSHOT (2020)
12.1.14 BIOM?RIEUX SA
TABLE 292 BIOM?RIEUX SA: BUSINESS OVERVIEW
FIGURE 43 BIOM?RIEUX SA: COMPANY SNAPSHOT (2020)
12.1.15 FUJIFILM HOLDINGS CORPORATION
TABLE 293 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 44 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
12.2 START-UP/SME PLAYERS
12.2.1 QUIDEL CORPORATION
TABLE 294 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 45 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
12.2.2 EXACT SCIENCES
TABLE 295 EXACT SCIENCES: BUSINESS OVERVIEW
FIGURE 46 EXACT SCIENCES: COMPANY SNAPSHOT (2020)
12.2.3 BIOCARTIS NV
TABLE 296 BIOCARTIS NV: BUSINESS OVERVIEW
FIGURE 47 BIOCARTIS NV: COMPANY SNAPSHOT (2020)
12.2.4 CANCER DIAGNOSTICS INC.
TABLE 297 CANCER DIAGNOSTICS INC.: BUSINESS OVERVIEW
12.2.5 AMOY DIAGNOSTICS CO. LTD.
TABLE 298 AMOY DIAGNOSTICS CO. LTD.: BUSINESS OVERVIEW
12.2.6 BIO-RAD LABORATORIES
TABLE 299 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 48 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
12.2.7 BIO SB
TABLE 300 BIO SB: BUSINESS OVERVIEW
12.2.8 VELA DIAGNOSTICS
TABLE 301 VELA DIAGNOSTICS: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, SWOT Analysis, and Right to Win might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 6 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 COVID-19 HEALTH ASSESSMENT
2.7 COVID-19 ECONOMIC ASSESSMENT
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
3 EXECUTIVE SUMMARY
FIGURE 10 CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021 VS. 2026 (USD BILLION)
FIGURE 11 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD BILLION)
FIGURE 12 CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION)
FIGURE 13 CANCER DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
FIGURE 14 CANCER DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD BILLION)
4 PREMIUM INSIGHTS
4.1 CANCER DIAGNOSTICS MARKET OVERVIEW
FIGURE 15 INCREASING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
DURING THE FORECAST PERIOD
4.2 CANCER DIAGNOSTICS MARKET, BY PRODUCT
FIGURE 16 INSTRUMENTS SEGMENT ACCOUNTED FOR THE LARGEST
MARKET SHARE IN 2020
4.3 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY, 2020
FIGURE 17 US DOMINATED THE NORTH AMERICAN CANCER DIAGNOSTICS
MARKET IN 2020
4.4 GEOGRAPHICAL SNAPSHOT OF THE CANCER DIAGNOSTICS MARKET
FIGURE 18 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 CANCER DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of cancer
TABLE 1 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS.
2030 VS. 2040 (MILLION)
TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
5.2.1.2 Growth in the number of private diagnostic centers
5.2.1.3 Availability of reimbursement
5.2.2 RESTRAINTS
5.2.2.1 High capital investments and low cost-benefit ratio for biomarkers
5.2.2.2 High cost of diagnostic imaging systems
5.2.2.3 Product recalls and failure
5.2.3 OPPORTUNITIES
5.2.3.1 Growing focus on personalized medicine
FIGURE 20 RISING NUMBER OF PERSONALIZED MEDICINES, 2008–2020
5.2.3.2 Companion diagnostics
5.2.3.3 Recommendations for cancer screening
5.2.3.4 Emerging countries
5.2.4 CHALLENGES
5.2.4.1 Increasing adoption of refurbished diagnostic imaging systems
5.2.4.2 Lack of skilled professionals
TABLE 3 NUMBER OF PATHOLOGISTS PER 10,000 POPULATION, BY COUNTRY, 2018
5.2.4.3 Inadequate infrastructure and low awareness in middle- and
low-income countries
5.2.5 TRENDS
5.2.5.1 Rental agreements
5.3 COVID-19 IMPACT ANALYSIS
5.4 VALUE CHAIN ANALYSIS
FIGURE 21 MAJOR VALUE IS ADDED DURING THE MANUFACTURING &
ASSEMBLY PHASES
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 22 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.6 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT FROM NEW ENTRANTS
5.6.2 INTENSITY OF COMPETITIVE RIVALRY
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 BARGAINING POWER OF SUPPLIERS
5.6.5 THREAT FROM SUBSTITUTES
5.7 TECHNOLOGY ANALYSIS
5.8 REGULATORY LANDSCAPE
FIGURE 23 510(K) APPROVAL PROCESS
5.9 PATENT ANALYSIS
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR MAMMOGRAPHY SYSTEMS
TABLE 4 IMPORT DATA FOR MAMMOGRAPHY SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
TABLE 5 EXPORT DATA FOR MAMMOGRAPHY SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
5.10.2 TRADE ANALYSIS FOR MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS
TABLE 6 IMPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
TABLE 7 EXPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016—2020 (USD MILLION)
5.11 PRICING ANALYSIS
TABLE 8 PRICES OF CANCER DIAGNOSTIC PRODUCTS
5.12 ECOSYSTEM ANALYSIS: CANCER DIAGNOSTICS MARKET
5.12.1 ROLE IN ECOSYSTEM
5.13 YCC SHIFT
6 CANCER DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 9 CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 CONSUMABLES
TABLE 10 CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 11 CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2019–2026 (USD MILLION)
6.2.1 ANTIBODIES
6.2.1.1 Antibodies accounted for the largest share of the cancer diagnostic consumables market in 2020
TABLE 12 CANCER DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
6.2.2 KITS & REAGENTS
6.2.2.1 Use of kits is increasing among end users owing to their ease of use
TABLE 13 CANCER DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2019–2026 (USD MILLION)
6.2.3 PROBES
6.2.3.1 Abbott and Agilent Technologies are some of the leading players operating in this market segment
TABLE 14 CANCER DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2019–2026 (USD MILLION)
6.2.4 OTHER CONSUMABLES
TABLE 15 CANCER DIAGNOSTICS MARKET FOR OTHER CONSUMABLES, BY REGION, 2019–2026 (USD MILLION)
6.3 INSTRUMENTS
TABLE 16 CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 17 CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.1 PATHOLOGY-BASED INSTRUMENTS
TABLE 18 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 19 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.1 Slide staining systems
6.3.1.1.1 Slide staining systems accounted for the largest share of the pathology-based instruments market
TABLE 20 CANCER DIAGNOSTICS MARKET FOR SLIDE STAINING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.2 Tissue processing systems
6.3.1.2.1 Tissue processing systems are used for the automatic processing of tissue samples
TABLE 21 CANCER DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.3 Cell processors
6.3.1.3.1 Cell processors are used to remove unwanted matter from cytology samples
TABLE 22 CANCER DIAGNOSTICS MARKET FOR CELL PROCESSORS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.4 PCR instruments
6.3.1.4.1 Cost-effectiveness of PCR is driving the growth of this market segment
TABLE 23 CANCER DIAGNOSTICS MARKET FOR PCR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.5 NGS instruments
6.3.1.5.1 NGS is an emerging technology for cancer diagnostics
TABLE 24 CANCER DIAGNOSTICS MARKET FOR NGS INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.6 Microarrays
6.3.1.6.1 DNA microarrays are useful for the determination of primary sites in metastatic carcinomas
TABLE 25 CANCER DIAGNOSTICS MARKET FOR MICROARRAYS, BY REGION, 2019–2026 (USD MILLION)
6.3.1.7 Other pathology-based instruments
TABLE 26 CANCER DIAGNOSTICS MARKET FOR OTHER PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.2 IMAGING INSTRUMENTS
TABLE 27 CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 28 CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.3.2.1 CT systems
6.3.2.1.1 Technological advancements in CT to drive the growth of this market segment
TABLE 29 CANCER DIAGNOSTICS MARKET FOR CT SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.2.2 Ultrasound systems
6.3.2.2.1 Increasing incidence of cancer to drive the growth of this market segment
TABLE 30 CANCER DIAGNOSTICS MARKET FOR ULTRASOUND SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.2.3 MRI systems
6.3.2.3.1 Use of MRI in cancer diagnostics has increased
over the years
TABLE 31 CANCER DIAGNOSTICS MARKET FOR MRI SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.2.4 Mammography systems
6.3.2.4.1 Increasing incidence of breast cancer to drive the growth of this market segment
TABLE 32 CANCER DIAGNOSTICS MARKET FOR MAMMOGRAPHY SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.2.5 Nuclear imaging systems
6.3.2.5.1 Technological advancements in nuclear imaging systems to drive the growth of this market segment
TABLE 33 CANCER DIAGNOSTICS MARKET FOR NUCLEAR IMAGING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
6.3.3 BIOPSY INSTRUMENTS
6.3.3.1 Increasing prevalence of cancer to drive the growth of this
market segment
TABLE 34 CANCER DIAGNOSTICS MARKET FOR BIOPSY INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
7 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 35 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
7.2 IVD TESTING
TABLE 36 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 37 CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY REGION, 2019–2026 (USD MILLION)
7.2.1 POLYMERASE CHAIN REACTION
7.2.1.1 Physicians prefer PCR-based diagnostic tests as they provide simple representations of genomic data
TABLE 38 CANCER DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2019–2026 (USD MILLION)
7.2.2 IN SITU HYBRIDIZATION
7.2.2.1 ISH is used for the identification of specific mRNA species within sample cells
TABLE 39 CANCER DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2019–2026 (USD MILLION)
7.2.3 IMMUNOHISTOCHEMISTRY
7.2.3.1 Increasing use of IHC tests for cancer diagnostics to boost
the market growth
TABLE 40 CANCER DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2019–2020 (USD MILLION)
7.2.4 NEXT-GENERATION SEQUENCING
7.2.4.1 NGS dominated the IVD testing market in 2020
TABLE 41 CANCER DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
7.2.5 IMMUNOASSAY
7.2.5.1 Immunoassay segment accounted for the second-largest share of the cancer diagnostics market for IVD testing
TABLE 42 CANCER DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY REGION, 2019–2026 (USD MILLION)
7.2.6 MICROARRAY
7.2.6.1 Cost-effectiveness of the microarray technology to
support market growth
TABLE 43 CANCER DIAGNOSTICS MARKET FOR MICROARRAY, BY REGION, 2019–2026 (USD MILLION)
7.2.7 FLOW CYTOMETRY
7.2.7.1 Flow cytometry tools help to detect the number of chromosomes to determine the malignancy of a tumor
TABLE 44 CANCER DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY REGION, 2019–2026 (USD MILLION)
7.2.8 OTHER IVD TECHNOLOGIES
TABLE 45 CANCER DIAGNOSTICS MARKET FOR OTHER IVD TECHNOLOGIES, BY REGION, 2019–2026 (USD MILLION)
7.3 IMAGING TECHNOLOGIES
TABLE 46 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 47 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2019–2026 (USD MILLION)
7.3.1 MAGNETIC RESONANCE IMAGING
7.3.1.1 Technological advancements to boost the growth of the MRI market
TABLE 48 CANCER DIAGNOSTICS MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2019–2026 (USD MILLION)
7.3.2 COMPUTED TOMOGRAPHY
7.3.2.1 CT is a widely used technique in cancer diagnostics
TABLE 49 CANCER DIAGNOSTICS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2019–2026 (USD MILLION)
7.3.3 NUCLEAR IMAGING
7.3.3.1 PET is a widely used nuclear imaging technique in cancer diagnostics
TABLE 50 CANCER DIAGNOSTICS MARKET FOR NUCLEAR IMAGING, BY REGION, 2019–2026 (USD MILLION)
7.3.4 MAMMOGRAPHY
7.3.4.1 Increasing government initiatives for breast cancer screening to drive the growth of this market segment
TABLE 51 CANCER DIAGNOSTICS MARKET FOR MAMMOGRAPHY, BY REGION, 2019–2026 (USD MILLION)
7.3.5 ULTRASOUND
7.3.5.1 Adoption of POC ultrasound for diagnostic purposes to support market growth
TABLE 52 CANCER DIAGNOSTICS MARKET FOR ULTRASOUND, BY REGION, 2019–2026 (USD MILLION)
7.4 BIOPSIES
TABLE 53 CANCER DIAGNOSTICS MARKET FOR BIOPSIES, BY REGION, 2019–2026 (USD MILLION)
8 CANCER DIAGNOSTICS MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 54 CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
8.2 BREAST CANCER
8.2.1 BREAST CANCER SEGMENT TO ACCOUNT FOR THE LARGEST SHARE DURING THE FORECAST PERIOD
TABLE 55 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 56 CANCER DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
8.3 LUNG CANCER
8.3.1 LUNG CANCER SEGMENT ACCOUNTED FOR THE SECOND-
LARGEST SHARE IN 2020
TABLE 57 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 58 CANCER DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
8.4 COLORECTAL CANCER
8.4.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO
DRIVE MARKET GROWTH
TABLE 59 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 60 CANCER DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2026 (USD MILLION)
8.5 MELANOMA
8.5.1 INCREASING INCIDENCE OF MELANOMA TO DRIVE MARKET GROWTH
TABLE 61 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 62 CANCER DIAGNOSTICS MARKET FOR MELANOMA, BY REGION, 2019–2026 (USD MILLION)
8.6 OTHER CANCERS
TABLE 63 CANCER DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
9 CANCER DIAGNOSTICS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 64 CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 HOSPITALS
9.2.1 HOSPITALS ARE THE LARGEST END USERS OF
CANCER DIAGNOSTIC PRODUCTS
TABLE 65 CANCER DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2019–2026 (USD MILLION)
9.3 DIAGNOSTIC LABORATORIES
9.3.1 INCREASING INCIDENCE OF CANCER TO DRIVE THE GROWTH OF
THIS SEGMENT
TABLE 66 CANCER DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
10 CANCER DIAGNOSTICS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 67 CANCER DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 24 NORTH AMERICA: CANCER DIAGNOSTICS MARKET SNAPSHOT
TABLE 68 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 69 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 70 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 71 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 72 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 73 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 74 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 75 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 76 NORTH AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 77 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 78 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 US is expected to be dominant in the North American market
TABLE 79 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 80 US: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 81 US: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 82 US: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 83 US: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 84 US: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 85 US: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 86 US: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 US: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 US: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 89 US: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 High prevalence of cancer in Canada is expected to
support market growth
TABLE 90 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 91 CANADA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 92 CANADA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 93 CANADA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 94 CANADA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 95 CANADA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 96 CANADA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 97 CANADA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 98 CANADA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 99 CANADA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 100 CANADA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 101 EUROPE: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 102 EUROPE: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 103 EUROPE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 104 EUROPE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 EUROPE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 106 EUROPE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 107 EUROPE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 108 EUROPE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 109 EUROPE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 110 EUROPE: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 111 EUROPE: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth
TABLE 112 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 113 GERMANY: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 114 GERMANY: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 115 GERMANY: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 GERMANY: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 GERMANY: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 118 GERMANY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 119 GERMANY: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 120 GERMANY: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 GERMANY: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 122 GERMANY: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Government initiatives to drive market growth in the UK
TABLE 123 UK: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 124 UK: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 125 UK: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 126 UK: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 127 UK: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 128 UK: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 129 UK: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 130 UK: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 131 UK: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 132 UK: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government funding for cancer diagnosis and prevention to support the market growth
TABLE 133 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 134 FRANCE: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 135 FRANCE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 136 FRANCE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 137 FRANCE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 138 FRANCE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 139 FRANCE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 140 FRANCE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 141 FRANCE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 142 FRANCE: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 143 FRANCE: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 High incidence of cancer to support the market growth in Italy
TABLE 144 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 145 ITALY: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 146 ITALY: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 147 ITALY: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 148 ITALY: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 149 ITALY: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 150 ITALY: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 151 ITALY: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 152 ITALY: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 153 ITALY: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 154 ITALY: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 High incidence of chronic diseases to drive the market
growth in Spain
TABLE 155 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 156 SPAIN: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 157 SPAIN: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 158 SPAIN: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 159 SPAIN: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 160 SPAIN: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 161 SPAIN: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 162 SPAIN: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 163 SPAIN: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 164 SPAIN: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 165 SPAIN: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 166 LUNG CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025
TABLE 167 LIVER CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025
TABLE 168 BREAST CANCER INCIDENCE IN KEY ROE COUNTRIES, 2018 VS. 2025
TABLE 169 ROE: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 170 ROE: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 171 ROE: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 172 ROE: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 173 ROE: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 174 ROE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 175 ROE: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 176 ROE: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 177 ROE: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 178 ROE: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 25 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET SNAPSHOT
TABLE 179 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 180 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 181 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 182 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 183 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-
BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 184 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 185 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 186 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 187 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 188 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 189 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Increasing healthcare expenditure to drive market growth in China
TABLE 190 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 191 CHINA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 192 CHINA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 193 CHINA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 194 CHINA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 CHINA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 196 CHINA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 197 CHINA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 198 CHINA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 199 CHINA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 200 CHINA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Advanced healthcare infrastructure to support market
growth in Japan
TABLE 201 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 202 JAPAN: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 203 JAPAN: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 204 JAPAN: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 205 JAPAN: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 206 JAPAN: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 207 JAPAN: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 208 JAPAN: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 209 JAPAN: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 210 JAPAN: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 211 JAPAN: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Expanding healthcare sector in the country to drive market growth
TABLE 212 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 213 INDIA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 214 INDIA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 215 INDIA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 216 INDIA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 217 INDIA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 218 INDIA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 219 INDIA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 220 INDIA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 221 INDIA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 222 INDIA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 223 INCIDENCE OF CANCER IN ROAPAC COUNTRIES
TABLE 224 ROAPAC: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 225 ROAPAC: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 226 ROAPAC: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 227 ROAPAC: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 228 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 229 ROAPAC: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 230 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 231 ROAPAC: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 232 ROAPAC: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 233 ROAPAC: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 234 ROW: CANCER DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 235 ROW: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 236 ROW: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 237 ROW: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 238 ROW: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 239 ROW: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 240 ROW: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 241 ROW: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 242 ROW: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 243 ROW: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 244 ROW: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5.1 LATIN AMERICA
10.5.1.1 Increasing number of cancer screening programs to
support market growth
TABLE 245 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 246 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 247 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 248 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 249 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 250 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 251 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-
BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 252 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 253 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 254 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 255 LATIN AMERICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 256 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 257 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5.2 MIDDLE EAST & AFRICA
10.5.2.1 Increasing incidence of cancer in the Middle East & Africa to
drive market growth
TABLE 258 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 259 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 260 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 261 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 262 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 263 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IMAGING INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 264 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 265 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IVD TESTING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 266 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 267 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 268 MIDDLE EAST & AFRICA: CANCER DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
FIGURE 26 KEY DEVELOPMENTS IN THE CANCER DIAGNOSTICS MARKET, JANUARY 2018–APRIL 2021
FIGURE 27 MARKET EVOLUTION MATRIX: JANUARY 2018 TO APRIL 2021
11.2 MARKET SHARE ANALYSIS
TABLE 269 CANCER DIAGNOSTICS MARKET FOR IMAGING TECHNOLOGIES:
DEGREE OF COMPETITION
TABLE 270 CANCER DIAGNOSTICS MARKET FOR PATHOLOGY-BASED INSTRUMENTS: DEGREE OF COMPETITION
TABLE 271 CANCER DIAGNOSTICS MARKET FOR BIOPSY INSTRUMENTS:
DEGREE OF COMPETITION
11.3 COMPANY EVALUATION MATRIX
11.3.1 STARS
11.3.2 EMERGING LEADERS
11.3.3 PERVASIVE PLAYERS
11.3.4 PARTICIPANTS
FIGURE 28 VENDOR DIVE: CANCER DIAGNOSTICS MARKET
11.4 COMPETITIVE LEADERSHIP MAPPING (SMES/ START-UPS)
11.4.1 PROGRESSIVE COMPANIES
11.4.2 STARTING BLOCKS
11.4.3 RESPONSIVE COMPANIES
11.4.4 DYNAMIC COMPANIES
FIGURE 29 VENDOR DIVE MATRIX FOR SMES & START-UPS:
CANCER DIAGNOSTICS MARKET
11.5 COMPETITIVE SCENARIO
11.5.1 PRODUCT LAUNCHES & APPROVALS
TABLE 272 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2018–APRIL 2021
11.5.2 DEALS
TABLE 273 KEY DEALS, JANUARY 2018–APRIL 2021
11.5.3 OTHER DEVELOPMENTS
TABLE 274 OTHER KEY DEVELOPMENTS, JANUARY 2018–APRIL 2021
11.5.4 COMPANY FOOTPRINT
TABLE 275 COMPANY FOOTPRINT
TABLE 276 COMPANY PRODUCT FOOTPRINT
TABLE 277 COMPANY APPLICATION FOOTPRINT
TABLE 278 COMPANY GEOGRAPHICAL FOOTPRINT
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, and Right to Win)*
12.1.1 GE HEALTHCARE
TABLE 279 GE HEALTHCARE: BUSINESS OVERVIEW
FIGURE 30 GE HEALTHCARE: COMPANY SNAPSHOT (2020)
12.1.2 BECTON, DICKINSON AND COMPANY
TABLE 280 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 31 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
12.1.3 ROCHE DIAGNOSTICS
TABLE 281 F. HOFFMAN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
12.1.4 DANAHER CORPORATION
TABLE 282 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 33 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
12.1.5 THERMO FISHER SCIENTIFIC
TABLE 283 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
12.1.6 ABBOTT LABORATORIES
TABLE 284 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
12.1.7 QIAGEN N.V.
TABLE 285 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 36 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
12.1.8 AGILENT TECHNOLOGIES INC.
TABLE 286 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
FIGURE 37 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2020)
12.1.9 ILLUMINA, INC.
TABLE 287 ILLUMINA INC.: BUSINESS OVERVIEW
FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
12.1.10 SIEMENS HEALTHINEERS AG
TABLE 288 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
12.1.11 DIASORIN S.P.A.
TABLE 289 DIASORIN S.P.A.: BUSINESS OVERVIEW
FIGURE 40 DIASORIN S.P.A.: COMPANY SNAPSHOT (2019)
12.1.12 MYRIAD GENETICS INC.
TABLE 290 MYRIAD GENETICS INC.: BUSINESS OVERVIEW
FIGURE 41 MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2020)
12.1.13 HOLOGIC, INC.
TABLE 291 HOLOGIC, INC.: BUSINESS OVERVIEW
FIGURE 42 HOLOGIC INC.: COMPANY SNAPSHOT (2020)
12.1.14 BIOM?RIEUX SA
TABLE 292 BIOM?RIEUX SA: BUSINESS OVERVIEW
FIGURE 43 BIOM?RIEUX SA: COMPANY SNAPSHOT (2020)
12.1.15 FUJIFILM HOLDINGS CORPORATION
TABLE 293 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 44 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
12.2 START-UP/SME PLAYERS
12.2.1 QUIDEL CORPORATION
TABLE 294 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 45 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
12.2.2 EXACT SCIENCES
TABLE 295 EXACT SCIENCES: BUSINESS OVERVIEW
FIGURE 46 EXACT SCIENCES: COMPANY SNAPSHOT (2020)
12.2.3 BIOCARTIS NV
TABLE 296 BIOCARTIS NV: BUSINESS OVERVIEW
FIGURE 47 BIOCARTIS NV: COMPANY SNAPSHOT (2020)
12.2.4 CANCER DIAGNOSTICS INC.
TABLE 297 CANCER DIAGNOSTICS INC.: BUSINESS OVERVIEW
12.2.5 AMOY DIAGNOSTICS CO. LTD.
TABLE 298 AMOY DIAGNOSTICS CO. LTD.: BUSINESS OVERVIEW
12.2.6 BIO-RAD LABORATORIES
TABLE 299 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 48 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
12.2.7 BIO SB
TABLE 300 BIO SB: BUSINESS OVERVIEW
12.2.8 VELA DIAGNOSTICS
TABLE 301 VELA DIAGNOSTICS: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, SWOT Analysis, and Right to Win might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
The report “Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), by Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020”, analyzes and studies the major market drivers, restraints, and opportunities.
This market is expected to reach $13.1 Billion by 2020 from $7.1 Billion in 2015, and is poised to grow at a CAGR of 12.9% during the forecast period.
The global cancer diagnostics market is segmented on the basis of technology, application, and region.
Major players in the global Cancer Diagnostics System Market are
- Agilent Technologies, Inc. (U.S.)
- Thermo Fisher Scientific, Inc. (U.S.)
- Becton, Dickinson and Company (U.S.)
- Abbott Laboratories, Inc. (U.S.)
- C.R. Bard, Inc. (U.S.)
Based on technology, the cancer diagnostics market is categorized into platform-based and instrument-based. The instrument-based segment is expected to account for a major share of the cancer diagnostics market, by product, in 2015.
Based on the application, the cancer diagnostics market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, and others. Breast cancer application is expected to account for a major share of the cancer diagnostics market, by application in 2015.
On the basis of region, the market is divided into North America, Europe, Asia, and Rest of the World (RoW). Rest of the World comprises Latin America, Pacific countries, and Middle East and Africa. North America is expected to account for the largest share in the cancer diagnostics market, followed by Europe and Asia. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies operating in the cancer diagnostics market.
The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms. Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market. However, shortage of trained and skilled personnel poses as a restraint to the market growth of cancer diagnostics. Rise in aging population and increasing cancer cases are likely to create huge opportunity for cancer diagnostics.
